<?xml version="1.0" encoding="UTF-8"?>
<p id="par0080">There is no conclusive evidence for the indications of this product. As a preliminary result from the literature and from consensus among experts (mainly related to experiences made recently in Asia), eligible patients must have laboratory confirmed COVID-19 (better if NAT positive but seronegative) and must have severe or rapidly progressive or immediately life-threatening COVID-19. It would be, however, advisable to consider, in a controlled study, the use of immune plasma also in patients in an earlier stage of the disease.</p>
